Last reviewed · How we verify

Sevoflurane / Remifentanil — Competitive Intelligence Brief

Sevoflurane / Remifentanil (Sevoflurane / Remifentanil) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: General anesthetic (sevoflurane) + opioid analgesic (remifentanil). Area: Anesthesiology.

marketed General anesthetic (sevoflurane) + opioid analgesic (remifentanil) GABA receptors (sevoflurane); mu-opioid receptor (remifentanil) Anesthesiology Small molecule Live · refreshed every 30 min

Target snapshot

Sevoflurane / Remifentanil (Sevoflurane / Remifentanil) — Technical University of Munich. Sevoflurane is a volatile anesthetic that depresses central nervous system activity, while remifentanil is an opioid agonist that provides analgesia and enhances anesthesia.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Sevoflurane / Remifentanil TARGET Sevoflurane / Remifentanil Technical University of Munich marketed General anesthetic (sevoflurane) + opioid analgesic (remifentanil) GABA receptors (sevoflurane); mu-opioid receptor (remifentanil)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (General anesthetic (sevoflurane) + opioid analgesic (remifentanil) class)

  1. Technical University of Munich · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Sevoflurane / Remifentanil — Competitive Intelligence Brief. https://druglandscape.com/ci/sevoflurane-remifentanil. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: